Clinical Trial News | Page 6 of 7 | www.PharmaNewsDaily.com

Home » Archives by category » Clinical Trial News (Page 6)

Prevacus to use blinktbi’s EyeStat in phase 1 concussion drug trial

July 15, 2018 No Comment

Clinical trial news : US biopharma company Prevacus has forged a partnership with medical device company blinktbi to use the latter’s EyeStat as an objective biomarker of brain function during a phase 1 clinical trial of a concussion drug. EyeStat is expected to deliver quick and objective data regarding neurological function by capturing and measuring […]

Lilly’s ramucirumab fails to crack phase 3 gastric cancer trial

December 11, 2017 No Comment

Eli Lilly and Company, which is better known as Lilly, says that a late-stage trial of Cyramza (ramucirumab) for the treatment of a form of gastric cancer met its primary goal of stopping the disease from advancing, but failed in improving overall survival. An antiangiogenic therapy, ramucirumab in combination with cisplatin and capecitabine or 5-FU […]

Amgen cholesterol drug Repatha bags FDA approval for preventing heart attack and stroke

December 9, 2017 No Comment

Repatha FDA approval news : Repatha (evolocumab), the Amgen cholesterol drug has bagged the approval from the US Food and Drug Administration (FDA) for the prevention of heart attacks, strokes and coronary revascularizations in heart disease patients. The Amgen cholesterol injection is a human monoclonal antibody which has been designed to block the activities of […]

Lilly’s breast cancer drug abemaciclib meets objective in phase 3 trial

March 22, 2017 No Comment

Indianapolis-based Lilly has reported that its breast cancer drug, abemaciclib, in combination with fulvestrant, has yielded positive results by meeting its primary endpoint, progression-free survival (PFS) in a phase 3 breast cancer trial. The combination of Lilly breast cancer drug abemaciclib with fulvestrant was proved to be more effective than the fulvestrant plus placebo combination […]

New oral blood thinner rivaroxaban from Bayer and Jannsen shown to cut recurrence of life-threatening blood clots

March 19, 2017 No Comment

Bayer and Janssen Pharmaceuticals have revealed that their jointly developed oral blood thinner Xarelto (rivaroxaban) had considerably brought down the risk of recurring formation of life-threatening blood clots in the vein as per the findings of their late-breaking study. Rivaroxaban Blood Thinner Clinical Trial This, they demonstrated in a blood thinner clinical trial dubbed EINSTEIN CHOICE. […]

Astrazeneca ovarian cancer drug Lynparza shown to improve survival chances

March 18, 2017 No Comment

Pharma giant AstraZeneca has reported that its ovarian cancer drug Lynparza (olaparib) as a maintenance therapy has considerably improved the survival chances of patients with germline BRCA-mutations (gBRCA) who had a relapse of the disease, who did not respond to platinum-based chemo. Phase 3 Trial of Astrazeneca Ovarian Cancer Drug Lynparza The observation of the […]

Amgen cholesterol injection Repatha reduces heart attack, stroke chances

March 18, 2017 No Comment

Amgen cholesterol injection Repatha (evolocumab) has been demonstrated to have cut heart attack and stroke risk by 20% in a phase 3 cardiovascular outcomes study featuring 27,564 patients with heart diseases. Amgen Cholesterol Trial for Repatha Cholesterol Injection During the trial, it was proven that by maximum reduction of low-density lipoprotein cholesterol (LDL-C) levels (bad cholesterol) […]

Tigenix’ heart attack stem cell therapy trial delivers positive results

March 13, 2017 No Comment

TiGenix has announced that its cardiac stem cell study assessing its heart attack stem cell therapy with AlloCSC-01 was successful in patients having the risk of heart failure following a coronary attack. Tigenix Heart Attack Stem Cell Therapy with AlloCSC-01 The Belgium biopharma stated that its Phase I/II study of donor-derived expanded cardiac stem cells (AlloCSC) […]

Eczema drug Dupixent succeeds in phase 3 atopic dermatitis clinical trial

March 5, 2017 No Comment

Atopic dermatitis clinical trial : The jointly developed eczema drug, Dupixent (dupilumab) from Sanofi and Regeneron Pharmaceuticals has met the primary endpoints of a crucial one-year long phase 3 clinical trial in adult patients with uncontrolled moderate-to-severe atopic dermatitis (AD). Update : Dupixent eczema injection gets FDA approval for atopic dermatitis treatment Atopic Dermatitis Clinical Trial […]

Roche breast cancer drug combo cuts death rate and recurrence

March 2, 2017 No Comment

Roche breast cancer drug, Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy has been demonstrated in a phase 3 trial to have cut the risk of disease recurrence besides increasing the life span of patients with an aggressive form of early breast cancer. Roche Breast Cancer Trial APHINITY Results The breast cancer drug combination which met […]